Uveitis Treatment Market To Reach $3.36 Billion by 2035

Uveitis treatment market is projected to grow significantly from $1.90 billion in 2025 to $3.36 billion by 2035, registering a CAGR of 5.86% during the forecast period (2026–2035). The market expansion is primarily driven by the increasing global burden of inflammatory eye diseases, rising awareness regarding early diagnosis, and advancements in biologic therapies.

A key macro driver supporting market growth is the increasing prevalence of vision impairment and blindness worldwide. According to the World Health Organization (WHO), over 2.2 billion people globally suffer from vision impairment, with a significant proportion caused by inflammatory conditions such as uveitis. Additionally, the WHO reports that early diagnosis and treatment can prevent up to 80% of visual impairment cases, highlighting the critical role of therapeutic interventions in managing ocular diseases.

Browse the full report description of “Uveitis Treatment Market Size, Share & Trends Analysis Report, By Disease Type (Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis), By Drug Class (Corticosteroids, Immunosuppressants, Biologics, Anti-infective Agents, Cycloplegic Agents), By End User (Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/uveitis-treatment-market

From an end-user perspective, healthcare infrastructure expansion and ophthalmology service utilization are accelerating treatment adoption. Data from the Organisation for Economic Co-operation and Development (OECD) indicates a steady rise in specialist consultations across developed nations, including ophthalmology visits, driven by aging populations and chronic disease prevalence. This trend is directly influencing demand for advanced uveitis treatments, particularly in hospital and specialty clinic settings.

Among the segments, Biologics under Drug Class is emerging as the fastest-growing segment due to its targeted mechanism of action and increasing regulatory approvals. Biologic therapies offer improved efficacy in treating chronic and non-infectious uveitis, especially in patients resistant to corticosteroids and immunosuppressants. The growing pipeline of monoclonal antibodies and immunomodulators is expected to further accelerate segment growth.

Recent Developments

• In November 2025, EyePoint Pharmaceuticals announced advancements in sustained-release ocular drug delivery through its DuraCert platform and Duravyu (vorolanib insert). The company progressed Phase 3 trials for retinal diseases, highlighting long-acting therapy potential.
  These innovations emphasize reduced treatment burden and targeted inflammation control.
• In January 2026, Novaliq received U.S. FDA IND clearance for NOV05 (tacrolimus ophthalmic solution) to initiate a Phase II trial in non-infectious anterior uveitis.
  The therapy is a steroid-free topical treatment, targeting intraocular inflammation—an unmet need in uveitis care.
  The study aims to validate EyeSol® technology for delivering drugs to inner-eye tissues.
  This development highlights ongoing innovation in uveitis treatment approaches.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Disease Type
  • By Drug Class
  • By End Users
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – AbbVie Inc, Bausch+ Lomb, Alimera Sciences, Eye Point, Allergan, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Uveitis Treatment Market Report Segment

By Disease Type

• Anterior Uveitis
• Intermediate Uveitis
• Posterior Uveitis
• Panuveitis

By Drug Class

• Corticosteroids
• Immunosuppressants
• Biologics
• Anti-infective Agents
• Cycloplegic Agents

By End User

• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers (ASCs)

Global Uveitis Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uveitis-treatment-market